The preclinical and clinical data supporting Celladon's case Odds for CUPID-2's success Potential outcomes for the stock price That enzyme is called SERCA2a and is critical for the contraction of the ...
Celladon Corporation (Nasdaq: CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it ...
SAN DIEGO, CA — Despite earlier promise in a small dose-finding study, a novel gene-based, single-dose treatment for heart failure failed to make a significant difference in a primary end point ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback